GB 004
Alternative Names: AKB-4924; GB-004Latest Information Update: 30 Mar 2026
At a glance
- Originator Procter & Gamble
- Developer Aerpio Pharmaceuticals; Gossamer Bio
- Class Anti-inflammatories; Piperazines; Pyridones; Small molecules
- Mechanism of Action Hypoxia inducible factor 1 modulators; Prolyl hydroxylase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 30 Mar 2026 Discontinued - Phase-I for Inflammatory bowel diseases (In volunteers) in Canada (PO) before March 2026 (Whitehawk Therapeutics pipeline, March 2026)
- 30 Mar 2026 Discontinued - Phase-II for Ulcerative colitis (In adults, In the elderly) in Russia (PO) before March 2026 (Whitehawk Therapeutics pipeline, March 2026)
- 30 Mar 2026 Discontinued - Phase-II for Ulcerative colitis (In adults, In the elderly) in South Korea (PO) before March 2026 (Whitehawk Therapeutics pipeline, March 2026)